Less than 2 months before the opening of the call for proposal!
Innovation Prize 2015
Join us as a partner for this new edition!
Open to young innovative companies, academic and private researchers, the Universal Biotech Innovation Prize aims to acknowledge on an international scale, the most innovative early stage projects in life sciences.
The Innovation Prize has become a recognized and essential event in the field of life sciences. The work performed by the jury members in recent years has made this event a real driver for innovation on the international stage
Focus on the 5 finalists of the previous edition :
Click on the finalists pictures in order to access to the summaries of the projets. Asceneuron – Christoph Wiessner – COO CarThera – Frédéric Sottilini – CEO Implandata Ophtalmic Products GmbH – Max Ostermeier – CEO iTeos Therapeutics – Michel Detheux – CEO* G-Therapeutics – Vincent Delattre – CEO
Do not hesitate to contact us by filling in the form below to download the Innovation Prize Brochure and to obtain more information on the different partnership opportunities.
Less than 2 months before the opening of the call for proposal!
[email-download download_id=”2476″ contact_form_id=”2542″]
Asceneuron
Christoph Wiessner – COO
Asceneuron develops a highly innovative drug for neurodegenerative diseases caused by the protein Tau. Their drug prevents Tau toxicity by targeting the enzyme O-GlcNAcase. It is planned to be first developed for Progressive supranuclear palsy (PSP), a fatal neurodegenerative disease that has no known treatment. PSP is an orphan (rare) disease and progresses very rapidly. The combination of well-defined drug-target, orphan disease, and the rapid progression of the disease is anticipated to quickly deliver a desperately needed treatment option for PSP patients. It can then be applied to other Tauopathies, including Alzheimer’s disease.
CarThera
Frédéric Sottilini – CEO
The prognosis of patients with brain tumors is dramatically low. Through the research efforts of Pr. Carpentier (neurosurgeon at Hospital Pitié-Salpêtrière – Paris) the developments of CarThéra aim to improve the prognosis of these patients using clinical stage medical devices. These devices are based on therapeutic ultrasound technology and allow for the diagnosis, treatment, and removal of tumors in a minimally invasive outpatient procedure (SonoProbe®) as well as for an improvement in the bioavailability of chemotherapeutics (SonoCloud®) by transiently opening the blood-brain barrier.
Implandata Ophtalmic Products GmbH
Max Ostermeier – CEO
Implandata Ophtalmic Products GmbH is an ophthalmic device company, offering the most advanced solution for improved glaucoma care. Glaucoma is a chronic disease and globally the number one reason for irreversible vision loss, caused by elevated intraocular pressure (IOP). With an implantable intraocular pressure sensor developed by us, it is possible for the first time to measure circadian IOP variations and IOP between office visits. By telemedical integration, it is possible to remotely manage glaucoma patients at lower cost and resulting in a better disease outcome.
iTeos Therapeutics
Michel Detheux – CEO
iTeos is a private, biology-driven and preclinical-stage company, that leverages Catholic University of Louvain & Ludwig Cancer Research’s tumor immunology unique expertise to focus on discovery and development of small molecules designed to modify the tumor microenvironment.
It will allow to target cancer-induced immune suppression resistance mechanism and enhance the clinical efficacy of cancer treatments. Current pipeline is focused on inhibitors of indoleamine-2,3-dioxygenase and tryptophan-2,3-dioxygenase, for which iTeos plans to complete the preclinical development by 2016.
*Stefano Crosignani Director, Medicinal Chemistry of iTeos, has represented iTeos during Innovation Days. Pic n°4
G-Therapeutics
Vincent Delattre – CEO
Ten years of academic research led to the development of fundamentally new treatment paradigms that restored voluntary locomotion in completely paralyzed animals with a success rate of 100%. G-therapeutics is translating these breakthroughs into a therapy for humans, and is developing an implantable spinal stimulation system and robotically assisted training program to rehabilitate spinal-cord-injured individuals. The team, consisting of several engineers and medical experts, has set-up a pioneering clinical proof of concept in humans, which has already received the ethical committee approval.
- 5th & 6th October 2015
